Here's What Key Metrics Tell Us About Humana (HUM) Q2 Earnings

Humana (HUM) reported $32.39 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.2%. EPS of $6.27 for the same period compares to $6.96 a year ago.The reported revenue represents a surprise of +1.93% over the Zacks Consensus Estimate of $31.78 billion. With the consensus EPS estimate being $6.32, the EPS surprise was -0.79%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Humana performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Benefits Expense Ratio - Consolidated: 89.7% compared to the 89.5% average estimate based on eight analysts.Medical Membership - Medicare Supplement: 444.1 thousand versus the four-analyst average estimate of 419.63 thousand.Medical Membership - State-based contracts and other: 1.58 million versus the four-analyst average estimate of 1.62 million.Medical Membership - Total Medicare: 8.23 million compared to the 8.19 million average estimate based on four analysts.Revenues- Premiums: $30.72 billion versus $30.23 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.Revenues- Investment income (loss): $272 million compared to the $270.96 million average estimate based on eight analysts. The reported number represents a change of -8.7% year over year.Revenues- Services: $1.4 billion compared to the $1.31 billion average estimate based on eight analysts. The reported number represents a change of +27.3% year over year.Insurance segment- Services revenue- Military services and other: $206 million compared to the $300.53 million average estimate based on six analysts. The reported number represents a change of 0% year over year.Revenue- CenterWell: $5.54 billion versus the six-analyst average estimate of $5.21 billion. The reported number represents a year-over-year change of +11.9%.Revenue- Insurance: $31.09 billion versus the six-analyst average estimate of $30.71 billion. The reported number represents a year-over-year change of +9%.CenterWell segment- Total Services revenue- External: $1.19 billion versus $1.05 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change.Total Intersegment Revenues- Eliminations/Corporate: $-4.34 billion compared to the $-4.18 billion average estimate based on five analysts. The reported number represents a change of +6.9% year over year.View all Key Company Metrics for Humana here>>>Shares of Humana have returned -7.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks